Pharma Mar, S.A. (PHM.MC)
EUR 76.95
(0.59%)
EUR 76.95
(0.59%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 0.06 EUR | -97.67% |
| 2022 | 2.73 EUR | -46.89% |
| 2021 | 5.14 EUR | -31.47% |
| 2020 | 7.50 EUR | 1600.0% |
| 2019 | -0.50 EUR | -66.67% |
| 2018 | -0.30 EUR | 79.31% |
| 2017 | -1.45 EUR | -10.69% |
| 2016 | -1.31 EUR | -463.89% |
| 2015 | 0.36 EUR | -50.0% |
| 2014 | 0.72 EUR | 20.0% |
| 2013 | 0.60 EUR | 126.32% |
| 2012 | -2.28 EUR | -2952.21% |
| 2011 | -0.07 EUR | 88.85% |
| 2010 | -0.67 EUR | 56.49% |
| 2009 | -1.54 EUR | 37.14% |
| 2008 | -2.45 EUR | 13.12% |
| 2007 | -2.82 EUR | -2.55% |
| 2006 | -2.75 EUR | -20.61% |
| 2005 | -2.28 EUR | -3034.36% |
| 2004 | 0.08 EUR | 104.95% |
| 2003 | -1.57 EUR | 25.59% |
| 2002 | -2.11 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 0.07 EUR | -46.08% |
| 2024 Q1 | 0.13 EUR | 133.33% |
| 2024 Q3 | 0.22 EUR | 213.84% |
| 2023 FY | - EUR | -97.67% |
| 2023 Q1 | 0.08 EUR | 1.56% |
| 2023 Q2 | 0.28 EUR | 259.44% |
| 2023 Q3 | 0.08 EUR | -69.79% |
| 2023 Q4 | -0.39 EUR | -560.99% |
| 2022 FY | - EUR | -46.89% |
| 2022 Q1 | 1.22 EUR | -42.45% |
| 2022 Q3 | 0.72 EUR | 0.0% |
| 2022 Q2 | 0.72 EUR | -40.98% |
| 2022 Q4 | 0.08 EUR | -89.35% |
| 2021 Q3 | 0.64 EUR | -39.62% |
| 2021 FY | - EUR | -31.47% |
| 2021 Q1 | 1.33 EUR | 291.18% |
| 2021 Q2 | 1.06 EUR | -20.3% |
| 2021 Q4 | 2.12 EUR | 231.25% |
| 2020 Q2 | 2.38 EUR | -37.7% |
| 2020 FY | - EUR | 1600.0% |
| 2020 Q4 | 0.34 EUR | -64.21% |
| 2020 Q1 | 3.82 EUR | 354.76% |
| 2020 Q3 | 0.95 EUR | -60.08% |
| 2019 Q2 | -0.59 EUR | -3.51% |
| 2019 Q4 | 0.84 EUR | 370.97% |
| 2019 Q1 | -0.57 EUR | 0.0% |
| 2019 FY | - EUR | -66.67% |
| 2019 Q3 | -0.31 EUR | 47.46% |
| 2018 Q3 | 0.11 EUR | -54.17% |
| 2018 Q4 | -0.57 EUR | -618.18% |
| 2018 FY | - EUR | 79.31% |
| 2018 Q1 | -0.07 EUR | 89.34% |
| 2018 Q2 | 0.24 EUR | 436.13% |
| 2017 Q1 | -0.13 EUR | 68.29% |
| 2017 Q4 | -0.67 EUR | -76.32% |
| 2017 Q3 | -0.38 EUR | -40.74% |
| 2017 FY | - EUR | -10.69% |
| 2017 Q2 | -0.27 EUR | -107.69% |
| 2016 Q4 | -0.41 EUR | -115.79% |
| 2016 FY | - EUR | -463.89% |
| 2016 Q3 | -0.19 EUR | 42.42% |
| 2016 Q2 | -0.33 EUR | 15.38% |
| 2016 Q1 | -0.39 EUR | -550.0% |
| 2015 FY | - EUR | -50.0% |
| 2015 Q3 | 0.24 EUR | 233.33% |
| 2015 Q1 | 0.36 EUR | 250.0% |
| 2015 Q2 | -0.18 EUR | -150.0% |
| 2015 Q4 | -0.06 EUR | -125.0% |
| 2014 Q4 | -0.24 EUR | -671.43% |
| 2014 Q2 | -0.01 EUR | -100.87% |
| 2014 Q1 | 0.92 EUR | 713.33% |
| 2014 FY | - EUR | 20.0% |
| 2014 Q3 | 0.04 EUR | 625.0% |
| 2013 Q2 | -0.08 EUR | -108.97% |
| 2013 Q1 | 0.86 EUR | 444.0% |
| 2013 FY | - EUR | 126.32% |
| 2013 Q4 | -0.15 EUR | -792.86% |
| 2013 Q3 | -0.02 EUR | 78.21% |
| 2012 Q2 | 0.84 EUR | 370.97% |
| 2012 Q4 | -0.25 EUR | -31.58% |
| 2012 FY | - EUR | -2952.21% |
| 2012 Q1 | -0.31 EUR | -173.81% |
| 2012 Q3 | -0.19 EUR | -122.62% |
| 2011 Q1 | -0.26 EUR | 29.73% |
| 2011 Q4 | 0.42 EUR | 216.67% |
| 2011 FY | - EUR | 88.85% |
| 2011 Q3 | -0.36 EUR | -320.07% |
| 2011 Q2 | -0.09 EUR | 67.04% |
| 2010 FY | - EUR | 56.49% |
| 2010 Q3 | -0.13 EUR | -96.67% |
| 2010 Q2 | -0.07 EUR | 39.91% |
| 2010 Q1 | -0.11 EUR | 84.51% |
| 2010 Q4 | -0.37 EUR | -184.62% |
| 2009 Q2 | -0.16 EUR | 23.81% |
| 2009 Q3 | -0.44 EUR | -175.0% |
| 2009 Q4 | -0.71 EUR | -61.36% |
| 2009 FY | - EUR | 37.14% |
| 2009 Q1 | -0.21 EUR | 79.41% |
| 2008 Q1 | -0.59 EUR | 0.0% |
| 2008 Q3 | -0.68 EUR | -778.55% |
| 2008 FY | - EUR | 13.12% |
| 2008 Q4 | -1.02 EUR | -50.0% |
| 2008 Q2 | -0.08 EUR | 86.88% |
| 2007 FY | - EUR | -2.55% |
| 2006 FY | - EUR | -20.61% |
| 2005 FY | - EUR | -3034.36% |
| 2004 FY | - EUR | 104.95% |
| 2003 FY | - EUR | 25.59% |
| 2002 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Atrys Health, S.A. | -0.60 EUR | 110.583% |
| Biotechnologies Assets SA | 0.03 EUR | -132.601% |
| Laboratorios Farmaceuticos Rovi, S.A. | 3.29 EUR | 98.07% |